Abstract

A novel angucycline, C1 isolated from Stereospermum fimbriatum stem bark was subjected to molecular docking studies on five main targets of penicillin-binding protein 2a (PBP2a), β-lactamase, DNA topoisomerase IV, dehydrosqualene synthase (CrtM) and sortase A (SrtA) for anti-MRSA activity. The binding sites and docking scores of known inhibitors (positive control) were compared with C1. Docking analysis was carried out by AutoDock 4.0 package. The binding site of C1 closely resembled the positive control in all screened receptors. Inhibition constant of C1 was lower than the positive control tested for PBP2a, β-lactamase, dehydrosqualene synthase and sortase A except against DNA Topoisomerase IV. Structure-activity relationship (SAR) analysis of C1 showed that 7-CO was the most significant contributor to its activity since it formed hydrogen bonds with four of the five screened receptors. Molecular docking of C1 indicated that C1 can be a good candidate for new anti-MRSA drug development.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.